It is important to highlight that there are no clinical trials specifically designed to evaluate the effect of GLP-1 Ras in reducing stroke as the primary objective, so the information is based on data on the risk of stroke as a secondary variable in clinical trials or post-hoc analysis thereof. This evidence concerns the gene GLP1R and stroke disorder.